784 related articles for article (PubMed ID: 25918390)
1. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Romano E; Kusio-Kobialka M; Foukas PG; Baumgaertner P; Meyer C; Ballabeni P; Michielin O; Weide B; Romero P; Speiser DE
Proc Natl Acad Sci U S A; 2015 May; 112(19):6140-5. PubMed ID: 25918390
[TBL] [Abstract][Full Text] [Related]
2. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.
Laurent S; Queirolo P; Boero S; Salvi S; Piccioli P; Boccardo S; Minghelli S; Morabito A; Fontana V; Pietra G; Carrega P; Ferrari N; Tosetti F; Chang LJ; Mingari MC; Ferlazzo G; Poggi A; Pistillo MP
J Transl Med; 2013 May; 11():108. PubMed ID: 23634660
[TBL] [Abstract][Full Text] [Related]
3. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
[TBL] [Abstract][Full Text] [Related]
4. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
Meyer C; Cagnon L; Costa-Nunes CM; Baumgaertner P; Montandon N; Leyvraz L; Michielin O; Romano E; Speiser DE
Cancer Immunol Immunother; 2014 Mar; 63(3):247-57. PubMed ID: 24357148
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
6. Activated Platelets Convert CD14
Lee SJ; Yoon BR; Kim HY; Yoo SJ; Kang SW; Lee WW
Front Immunol; 2020; 11():611133. PubMed ID: 33488616
[TBL] [Abstract][Full Text] [Related]
7. Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells.
Tsaknakis B; Schaefer IM; Schwörer H; Sahlmann CO; Thoms KM; Blaschke M; Ramadori G; Cameron S
Med Oncol; 2014 Jan; 31(1):813. PubMed ID: 24338272
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages.
Fujimura T; Kakizaki A; Kambayashi Y; Sato Y; Tanita K; Lyu C; Furudate S; Aiba S
Exp Dermatol; 2018 Jan; 27(1):64-70. PubMed ID: 28833504
[TBL] [Abstract][Full Text] [Related]
9. Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
Leontovich AA; Dronca RS; Nevala WK; Thompson MA; Kottschade LA; Ivanov LV; Markovic SN;
Melanoma Res; 2017 Feb; 27(1):32-42. PubMed ID: 27824739
[TBL] [Abstract][Full Text] [Related]
10. CD14+CD16+ and CD14+CD163+ monocyte subpopulations in kidney allograft transplantation.
Sekerkova A; Krepsova E; Brabcova E; Slatinska J; Viklicky O; Lanska V; Striz I
BMC Immunol; 2014 Feb; 15():4. PubMed ID: 24499053
[TBL] [Abstract][Full Text] [Related]
11. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
Callahan MK; Wolchok JD; Allison JP
Semin Oncol; 2010 Oct; 37(5):473-84. PubMed ID: 21074063
[TBL] [Abstract][Full Text] [Related]
12. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Arce Vargas F; Furness AJS; Litchfield K; Joshi K; Rosenthal R; Ghorani E; Solomon I; Lesko MH; Ruef N; Roddie C; Henry JY; Spain L; Ben Aissa A; Georgiou A; Wong YNS; Smith M; Strauss D; Hayes A; Nicol D; O'Brien T; Mårtensson L; Ljungars A; Teige I; Frendéus B; ; ; ; Pule M; Marafioti T; Gore M; Larkin J; Turajlic S; Swanton C; Peggs KS; Quezada SA
Cancer Cell; 2018 Apr; 33(4):649-663.e4. PubMed ID: 29576375
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.
Pico de Coaña Y; Poschke I; Gentilcore G; Mao Y; Nyström M; Hansson J; Masucci GV; Kiessling R
Cancer Immunol Res; 2013 Sep; 1(3):158-62. PubMed ID: 24777678
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
15. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
[TBL] [Abstract][Full Text] [Related]
17. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
[TBL] [Abstract][Full Text] [Related]
18. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
Patel SP; Woodman SE
Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
[TBL] [Abstract][Full Text] [Related]
19. An immune-active tumor microenvironment favors clinical response to ipilimumab.
Ji RR; Chasalow SD; Wang L; Hamid O; Schmidt H; Cogswell J; Alaparthy S; Berman D; Jure-Kunkel M; Siemers NO; Jackson JR; Shahabi V
Cancer Immunol Immunother; 2012 Jul; 61(7):1019-31. PubMed ID: 22146893
[TBL] [Abstract][Full Text] [Related]
20. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
Chakravarti N; Ivan D; Trinh VA; Glitza IC; Curry JL; Torres-Cabala C; Tetzlaff MT; Bassett RL; Prieto VG; Hwu WJ
Melanoma Res; 2017 Feb; 27(1):24-31. PubMed ID: 27768639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]